• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.

作者信息

Sier C F, Quax P H, Vloedgraven H J, Verheijen J H, Griffioen G, Ganesh S, Lamers C B, Verspaget H W

机构信息

Department of Gastroenterology and Hepatology, University Hospital, Leiden, The Netherlands.

出版信息

Invasion Metastasis. 1993;13(6):277-88.

PMID:7860221
Abstract

Human carcinomas of the oesophagus, stomach, colorectum, and their liver metastases were previously shown to have increased levels of the urokinase-type plasminogen activator (u-PA). The proteolytic activity of u-PA on the surface of tumour cells is thought to play a key role in invasion and metastasis of malignancies. Therefore, in this study we quantitatively determined the presence of specific u-PA receptors in human gastrointestinal carcinomas, premalignant colonic adenomas, liver metastases, and adjacent normal tissues. All carcinomas showed a 2- to 13-fold higher level of u-PA receptor than their corresponding normal tissues at both the antigen level (ELISA) and the mRNA level (Northern blotting). Colonic adenomas also showed enhanced levels of the u-PA receptor protein. The state of occupancy of the u-PA receptors was determined using a specific ligand-binding assay in which free u-PA receptors were cross-linked with 125I-u-PA and visualized by autoradiography. Colonic carcinomas and liver metastases contained higher levels of free u-PA receptor compared to their corresponding normal tissues. Acid treatment of the receptors prior to cross-linking did not enhance the u-PA/u-PA receptor complex formation. The free u-PA receptor levels in colonic adenomas and in oesophageal and stomach carcinomas showed less difference compared with their normal reference tissues. The increased presence of specific receptors for u-PA in gastrointestinal carcinomas, particularly primary colonic carcinomas and their metastatic lesions in the liver, emphasizes the involvement of the urokinase pathway of plasminogen activation in gastrointestinal carcinogenesis and renders it a putative target for clinical intervention.

摘要

相似文献

1
Increased urokinase receptor levels in human gastrointestinal neoplasia and related liver metastases.
Invasion Metastasis. 1993;13(6):277-88.
2
Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.尿激酶型纤溶酶原激活剂(u-PA)、u-PA受体及组织型纤溶酶原激活剂信使核糖核酸在人肝细胞癌中的表达
Cancer Res. 1998 May 15;58(10):2234-9.
3
Ethanol-induced up-regulation of the urokinase receptor in cultured human endothelial cells.乙醇诱导培养的人内皮细胞中尿激酶受体上调。
Alcohol Clin Exp Res. 2001 Feb;25(2):163-70.
4
Effect of heat shock on the expression of urokinase-type plasminogen activator receptor in human umbilical vein endothelial cells.热休克对人脐静脉内皮细胞中尿激酶型纤溶酶原激活物受体表达的影响。
Thromb Haemost. 1996 Feb;75(2):352-8.
5
Stable expression of antisense urokinase mRNA inhibits the proliferation and invasion of human hepatocellular carcinoma cells.反义尿激酶mRNA的稳定表达抑制人肝癌细胞的增殖和侵袭。
Cancer Gene Ther. 2003 Feb;10(2):112-20. doi: 10.1038/sj.cgt.7700533.
6
Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.尿激酶型纤溶酶原激活物、纤溶酶原激活物受体及纤溶酶原激活物抑制剂-2在正常人体子宫内膜和子宫内膜癌中的mRNA差异表达
Gynecol Oncol. 2000 Nov;79(2):244-50. doi: 10.1006/gyno.2000.5959.
7
In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.尿激酶型纤溶酶原激活剂及其受体在人膀胱移行细胞癌中的原位基因表达
Oncol Rep. 2004 Oct;12(4):909-13.
8
Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.尿激酶型纤溶酶原激活剂及其受体和抑制剂在肾细胞癌患者中的临床相关性。
Cancer. 1996 Aug 1;78(3):487-92. doi: 10.1002/(SICI)1097-0142(19960801)78:3<487::AID-CNCR16>3.0.CO;2-V.
9
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.尿激酶型纤溶酶原激活物及其受体和纤溶酶原激活物抑制剂-2在食管鳞状细胞癌中的细胞分布及临床价值
Am J Pathol. 2000 Feb;156(2):567-75. doi: 10.1016/S0002-9440(10)64761-X.
10
The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.胰腺癌中的纤溶酶原激活物系统:组织型纤溶酶原激活物在体外侵袭潜能中的作用。
Oncogene. 1998 Feb 5;16(5):625-33. doi: 10.1038/sj.onc.1201564.

引用本文的文献

1
CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy.新辅助治疗后病理完全缓解的直肠癌患者中癌胚抗原、上皮细胞黏附分子、αvβ6和尿激酶型纤溶酶原激活物受体的表达
Diagnostics (Basel). 2021 Mar 14;11(3):516. doi: 10.3390/diagnostics11030516.
2
Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma.尿激酶型纤溶酶原激活物受体提示免疫抑制特征,并作为胶质瘤的不良预后生物标志物。
Oncologist. 2021 Aug;26(8):e1460-e1469. doi: 10.1002/onco.13750. Epub 2021 Mar 28.
3
Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study.
肿瘤相关基质细胞中尿激酶型纤溶酶原激活物受体(uPAR)的表达与结直肠癌患者预后相关:一项组织芯片研究
BMC Cancer. 2014 Apr 17;14:269. doi: 10.1186/1471-2407-14-269.
4
Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target.肝细胞生长因子/c-Met信号通路在调节尿激酶型纤溶酶原激活物对人肝细胞癌侵袭性中的作用:一个潜在的治疗靶点。
Clin Exp Metastasis. 2008;25(1):89-96. doi: 10.1007/s10585-007-9106-6. Epub 2007 Nov 9.
5
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.尿激酶型纤溶酶原激活物及其受体和纤溶酶原激活物抑制剂-2在食管鳞状细胞癌中的细胞分布及临床价值
Am J Pathol. 2000 Feb;156(2):567-75. doi: 10.1016/S0002-9440(10)64761-X.
6
Urokinase type plasminogen activator receptor expression in colorectal neoplasms.尿激酶型纤溶酶原激活物受体在结直肠肿瘤中的表达
Gut. 1998 Dec;43(6):798-805. doi: 10.1136/gut.43.6.798.
7
Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.纤溶酶原激活剂及其抑制剂对杜克B期和C期结直肠癌患者生存预后的影响
Br J Cancer. 1997;75(12):1793-801. doi: 10.1038/bjc.1997.306.
8
In situ stromal expression of the urokinase/plasmin system correlates with epithelial dysplasia in colorectal adenomas.尿激酶/纤溶酶系统的原位基质表达与大肠腺瘤中的上皮发育异常相关。
Am J Pathol. 1997 Jan;150(1):283-95.
9
Increase of a urokinase receptor-related low-molecular-weight molecule in colorectal adenocarcinomas.结直肠癌中尿激酶受体相关低分子量分子的增加。
Clin Exp Metastasis. 1995 Nov;13(6):492-8. doi: 10.1007/BF00118188.